GB201502240D0 - Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels - Google Patents

Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels

Info

Publication number
GB201502240D0
GB201502240D0 GBGB1502240.3A GB201502240A GB201502240D0 GB 201502240 D0 GB201502240 D0 GB 201502240D0 GB 201502240 A GB201502240 A GB 201502240A GB 201502240 D0 GB201502240 D0 GB 201502240D0
Authority
GB
United Kingdom
Prior art keywords
composition
blood lipid
lactobacillus reuteri
lipid levels
decreasing blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1502240.3A
Other versions
GB2535177A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmont Biotech Inc
Original Assignee
Genmont Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmont Biotech Inc filed Critical Genmont Biotech Inc
Priority to GB1502240.3A priority Critical patent/GB2535177A/en
Publication of GB201502240D0 publication Critical patent/GB201502240D0/en
Publication of GB2535177A publication Critical patent/GB2535177A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GB1502240.3A 2015-02-11 2015-02-11 Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels Withdrawn GB2535177A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1502240.3A GB2535177A (en) 2015-02-11 2015-02-11 Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1502240.3A GB2535177A (en) 2015-02-11 2015-02-11 Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels

Publications (2)

Publication Number Publication Date
GB201502240D0 true GB201502240D0 (en) 2015-03-25
GB2535177A GB2535177A (en) 2016-08-17

Family

ID=52746434

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1502240.3A Withdrawn GB2535177A (en) 2015-02-11 2015-02-11 Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels

Country Status (1)

Country Link
GB (1) GB2535177A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114344344A (en) * 2022-01-05 2022-04-15 东北农业大学 Application of lactobacillus reuteri in relieving high-fat diet induced obesity of mice and compound containing lactobacillus reuteri

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220105141A1 (en) * 2018-06-26 2022-04-07 Genmont Biotech Incorporation Lactobacillus reuteri gmnl-263 for improving hypertension and its compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100909586B1 (en) * 2007-06-01 2009-07-27 신현길 Lactic acid bacteria and mixed strains thereof effective in lowering blood cholesterol levels
EP2392340B1 (en) * 2010-06-01 2014-01-08 GenMont Biotech Inc. Novel lactobacillus strain, composition and use thereof for treating diabetes
GB2522188B (en) * 2014-01-10 2016-09-21 Genmont Biotech Inc A lactobacillus reuteri GMNL-263 composition for controlling body weight and its use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114344344A (en) * 2022-01-05 2022-04-15 东北农业大学 Application of lactobacillus reuteri in relieving high-fat diet induced obesity of mice and compound containing lactobacillus reuteri

Also Published As

Publication number Publication date
GB2535177A (en) 2016-08-17

Similar Documents

Publication Publication Date Title
IL247775A0 (en) In vivo and in vitro use of graphene
SG11201703298SA (en) Activated bifidobacteria and methods of use thereof
EP3203902A4 (en) Quantification of absolute blood flow in tissue using fluorescence-mediated photoplethysmography
EP3133914A4 (en) Continuous cooker stretcher and methods of use thereof
HK1258349A1 (en) Hppd variants and methods of use
IL280690A (en) Pharmaceutical compositions comprising dgla and use of same
ZA201704726B (en) Peptides and their use in the treatment of skin
HK1218247A1 (en) Probiotics and methods of use
ZA201507319B (en) Cosmetic and pharmaceutical applications of lactobacillus pentosus
EP3060061A4 (en) Use of probiotics in meat
EP3433035A4 (en) Compositions and methods of use thereof in sandcasting
EP3253396A4 (en) Probiotic compositions and methods of use
IL260181A (en) Compositions and methods of use of novel strains of lactobacillus fermentum
EP3244903C0 (en) Preparation comprising lactobacillus reuteri and citrate for medical use
GB2524474B (en) Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes
GB201502240D0 (en) Composition and use of lactobacillus reuteri GMNL-263 in decreasing blood lipid levels
EP3528892A4 (en) Antioxidant-enriched multivitamin composition and methods of use
PL3454873T3 (en) Probiotic composition and uses thereof
PL3168292T3 (en) New lactobacillus plantarum strain amt14 and composition containing the strain of lactobacillus plantarum amt14
ZA201804198B (en) Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body
PL3166642T3 (en) Transdermal formulations of pergolide and uses thereof
GB2562322B (en) Furniture unit and method of use thereof
GB201602991D0 (en) Improved folding furniture and method of use thereof
ZA201403582B (en) Composition for use in treatment of anemia and low blood pressure
GB201504209D0 (en) Improved folding furniture and method of use thereof

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)